Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Unknown 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Head & Neck 1Gastrointestinal 1

Conditions

Squamous Cell Carcinoma of Head and Neck 1Nasopharyngeal Carcinoma 1Esophageal Squamous Cell Carcinoma 1

Interventions

pembrolizumab 3Cisplatin 3trametinib 2selpercatinib 2larotrectinib 2entrectinib 2dabrafenib 2Carboplatin 2ulixertinib 1trastuzumab biosimilar HLX02 1toripalimab 1sapanisertib 1repotrectinib 1relatlimab 1pralsetinib 1pertuzumab 1penpulimab 1palbociclib 1osimertinib 1omipalisib 1ipatasertib 1erdafitinib 1defactinib 1copanlisib 1capivasertib 1cabozantinib 1binimetinib 1adavosertib 1X-Rays 1Trastuzumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has announcements × toripalimab × Head & Neck × Clear all
NCT02915432 2021-12-13

The Study to Evaluate Toripalimab (JS001) in Patients With Advanced GC, ESCC, NPC, HNSCC

Shanghai Junshi Bioscience Co., Ltd.

Phase 1/2 Unknown
401 enrolled 1 FDA
GastrointestinalHead & Neck

Squamous Cell Carcinoma of Head and Neck, Nasopharyngeal Carcinoma, Esophageal Squamous Cell Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡